15 research outputs found
Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors
Get PDFHormone receptor positive (HR+) cancers account for most breast cancer diagnoses and deaths. Among survivors with HR+ breast cancers, endocrine therapy (ET) reduces 5-year risk of recurrence by up to 40%. Observational studies in Medicare and privately-insured survivors suggest under-utilization of ET. We sought to characterize ET use in a low-income Medicaid-insured population in North Carolina
Cost-effectiveness of alternative adjuvant bisphosphonate regimens in postmenopausal women with early breast cancer.
No full text
Measuring the effect of adjuvant chemotherapy on function-related adverse outcomes among older breast cancer patients.
No full textAssociation of race, reproductive factors, and lifestyle factors with tumor subtype defined by Oncotype DX recurrence score.
No full textEndocrine therapy adherence, side effects, and risk perception among racially diverse breast cancer patients.
No full textHow does parental status influence preferences for cancer treatment and palliative care?
No full text
Guideline-concordant surveillance and follow-up care among low-income patients with breast cancer: The role of primary care medical homes.
No full text
